ALK – Financial calendar for the 2026 financial year

Read more about ALK – Financial calendar for the 2026 financial year

Link

https://www.globenewswire.com/news-release/2025/12/22/3209361/0/en/ALK-Financia…

Created date

Mon, 12/22/2025 - 12:00

Nasdaq ID

3209361

Last updated: 2026.04.09

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

Read more about ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

Link

https://www.globenewswire.com/news-release/2026/01/08/3215621/0/en/ALK-to-prese…

Created date

Thu, 01/08/2026 - 12:00

Nasdaq ID

3215621

Last updated: 2026.04.09

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children

Read more about ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children

Link

https://www.globenewswire.com/news-release/2026/01/29/3228809/0/en/ALK-receives…

Created date

Thu, 01/29/2026 - 12:00

Nasdaq ID

3228809

Last updated: 2026.04.09

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

Read more about Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

Link

https://www.globenewswire.com/news-release/2026/02/13/3237968/0/en/Invitation-t…

Created date

Fri, 02/13/2026 - 12:00

Nasdaq ID

3237968

Last updated: 2026.04.09

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

Read more about Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

Link

https://www.globenewswire.com/news-release/2026/02/20/3241684/0/en/Annual-repor…

Created date

Fri, 02/20/2026 - 12:00

Nasdaq ID

3241684

Last updated: 2026.04.09

Henriette Mersebach to step down as ALK’s head of R&D

Read more about Henriette Mersebach to step down as ALK’s head of R&D

Link

https://www.globenewswire.com/news-release/2026/02/20/3241692/0/en/Henriette-Me…

Created date

Fri, 02/20/2026 - 12:00

Nasdaq ID

3241692

Last updated: 2026.04.09

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

Read more about Annual General Meeting in ALK-Abelló A/S on 16 March 2026

Link

https://www.globenewswire.com/news-release/2026/02/20/3241939/0/en/Annual-Gener…

Created date

Fri, 02/20/2026 - 12:00

Nasdaq ID

3241939

Last updated: 2026.04.09

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

Read more about New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

Link

https://www.globenewswire.com/news-release/2026/03/04/3249131/0/en/New-data-rev…

Created date

Wed, 03/04/2026 - 12:00

Nasdaq ID

3249131

Last updated: 2026.04.09

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

Read more about Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

Link

https://www.globenewswire.com/news-release/2026/03/16/3256594/0/en/Annual-Gener…

Created date

Mon, 03/16/2026 - 12:00

Nasdaq ID

3256594

Last updated: 2026.04.09

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

Read more about EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

Link

https://www.globenewswire.com/news-release/2026/03/31/3265184/0/en/EURneffy-1-m…

Created date

Tue, 03/31/2026 - 12:00

Nasdaq ID

3265184

Last updated: 2026.04.09

Subscribe to